These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4336739)

  • 1. Enhanced resistance of Corynebacterium parvum-treated mice to infection by bacteria.
    Adlam C; Broughton ES; Scott MT
    J Med Microbiol; 1972 Feb; 5(1):Pvii. PubMed ID: 4336739
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics of resistance to Listeria monocytogenes enhanced by Corynebacterium parvum in mice.
    Miyata H; Nomoto K; Takeya K
    Immunology; 1980 May; 40(1):33-9. PubMed ID: 6968291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the in-vitro antitumor activity of peritoneal cells from mice injected with Corynebacterium parvum and Corynebacterium liquefaciens.
    Toge T; Hattori T
    Hiroshima J Med Sci; 1979 Jun; 28(2):95-101. PubMed ID: 478988
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhanced resistance of mice to infection with bacteria following pre-treatment with Corynebacterium parvum.
    Adlam C; Broughton ES; Scott MT
    Nat New Biol; 1972 Feb; 235(59):219-20. PubMed ID: 4501536
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
    Hamilton DN; Bell PR
    Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice.
    Wolmark N; Levine M; Fisher B
    J Reticuloendothel Soc; 1974 Oct; 16(4):252-7. PubMed ID: 4455907
    [No Abstract]   [Full Text] [Related]  

  • 7. Bacterial products as immunomodulating agents.
    Gialdroni-Grassi G; Grassi C
    Int Arch Allergy Appl Immunol; 1985; 76 Suppl 1():119-27. PubMed ID: 2858453
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Corynebacterium parvum on cytotoxicity of regional and nonregional lymph node cells from animals with tumors present or removed.
    Fisher B; Wolmark N; Coyle J
    J Natl Cancer Inst; 1974 Dec; 53(6):1793-801. PubMed ID: 4471644
    [No Abstract]   [Full Text] [Related]  

  • 9. Macrophage activation and increased resistance to infection in immunosuppressed mice treated with Corynebacterium parvum vaccine or pyran copolymer.
    Stinnett JD; Morris MJ; Alexander JW
    J Reticuloendothel Soc; 1979 May; 25(5):525-31. PubMed ID: 458782
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunotherapy with Corynebacterium parvum in experimental influenza virus infections and mixed infections in mice].
    Denys A; Kowalska M; Szydłowska T; Białek J
    Pol Tyg Lek; 1986 May; 41(19):619-23. PubMed ID: 3763446
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative study of Corynebacterium parvum and Corynebacterium liquefaciens on antitumor activity against sarcoma-180.
    Ideda H; Yamagata S; Toge T; Hattori T
    Gan; 1977 Apr; 68(2):233-5. PubMed ID: 892298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of BCG and Corynebacterium Parvum on allograft survival after rabbit antimouse lymphocyte serum and donor bone marrow.
    Clark AW; Monaco AP
    Surg Forum; 1973; 24():340-3. PubMed ID: 4618660
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced resistance of mice to Mycoplasma pulmonis-induced arthritis by administration of killed Corynebacterium parvum.
    Keystone EC; Taylor-Robinson D; Ling L; Pope C; Metcalfe A; Furr P; Fornasier V
    Clin Exp Immunol; 1981 Nov; 46(2):355-62. PubMed ID: 7337973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased phagocytic cell activity and anaemia in Corynebacterium parvum treated mice.
    McBride WH; Jones JT; Weir DM
    Br J Exp Pathol; 1974 Feb; 55(1):38-46. PubMed ID: 4835797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. V. Comparison of the effects of tilorone hydrochloride, levamisole, methanol-soluble fraction of Mycobacterium butyricum, BCG, and a nonviable aqueous ether extract of Brucella abortus preparation in treatment of mice with tumors.
    Fisher B; Linta J; Hanlon J; Saffer E
    J Natl Cancer Inst; 1978 Feb; 60(2):391-9. PubMed ID: 413929
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor activity of a Brucella abortus preparation.
    Keleti G; Feingold DS; Youngner JS
    Infect Immun; 1977 Mar; 15(3):846-9. PubMed ID: 404249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation response of C3H fibrosarcoma enhanced in mice stimulated by Corynebacterium parvum.
    Suit HD; Sedlacek R; Wagner M; Orsi L
    Nature; 1975 Jun; 255(5508):493-4. PubMed ID: 1138200
    [No Abstract]   [Full Text] [Related]  

  • 19. Biological effects of Corynebacterium parvum. IV. Adjuvant and inhibitory activities on B lymphocytes.
    Howard JG; Christie GH; Scott MT
    Cell Immunol; 1973 May; 7(2):290-301. PubMed ID: 4350148
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection of mice against viral infection by Corynebacterium parvum and Bordetella pertussis.
    Kirchner H; Scott MT; Hirt HM; Munk K
    J Gen Virol; 1978 Oct; 41(1):97-104. PubMed ID: 212522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.